Sodium-Glucose Co-Transporter 2 Inhibitors and the Potential for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus

References

• . Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44( suppl 2):S14–S21
   PubMed Web of Science ®Google Scholar
• . Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156(8):714–719
   PubMed Web of Science ®Google Scholar
• . Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–393
   PubMed Web of Science ®Google Scholar
• . Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142–148
   PubMed Web of Science ®Google Scholar
• . Woerle HJ, Ferrannini E, Berk A, Manun'ebo M, Pinnetti S, Broedl UC. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes. Paper presented at: 72nd Annual Scientific Sessions of the American Diabetes Association; June 8–12, 2012; Philadelphia, PA
   Google Scholar
• . Gerstein HC, Bosch J, Dagenais GR, ; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328
   PubMed Web of Science ®Google Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Fisman EZ, Tenenbaum A, Boyko V, . Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol. 2001;24(2):151–158
   PubMed Web of Science ®Google Scholar
• . Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–936
   PubMed Web of Science ®Google Scholar
• . Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care. 2008;31(8):1672–1678
   PubMed Web of Science ®Google Scholar
• . Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–228
   PubMed Web of Science ®Google Scholar
• . Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev. 2004;20(1):44–47
   PubMed Web of Science ®Google Scholar
• . Monami M, Marchionni N, Masotti G, Mannucci E. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol. 2008;126(2):247–251
   PubMed Web of Science ®Google Scholar
• . Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–394
   PubMed Web of Science ®Google Scholar
• . Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004;20(3):239–245
   PubMed Web of Science ®Google Scholar
• . Tzoulaki I, Molokhia M, Curcin V, . Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• . Erdmann E, Song E, Spanheimer R, Van Troostenburg de Bruyn AR, Perez A. Pioglitazone and macrovascular outcomes during observational follow-up of PROactive: 6-year update. Paper presented at: 48th Annual Meeting of the European Association for the Study of Diabetes; 1–5 October, 2012; Berlin, Germany. Presentation 1228
   Google Scholar
• . Erdmann E, Spanheimer R, Charbonnel B; PROactive Study Investigators. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, reninangiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes. 2010;2(3):212–220
   PubMed Web of Science ®Google Scholar
• . INVOKANA™(canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013
   Google Scholar
• . Dapagliflozin (Forxiga) [package insert]. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001dl24. 2012. Accessed April 4, 2013
   Google Scholar
• . Vallon V, Platt KA, Cunard R, . SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22(1):104–112
   PubMed Web of Science ®Google Scholar
• . Devineni D, Morrow L, Hompesch M, . Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–545
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aggarwal N, Polidori D, ; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–1238
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes [published online ahead of print February 8, 2013]. Diabetes Obes Metab
   Google Scholar
• . Rosenstock J, Jelaska A, Seman LJ, Pinnetti S, Hantel S, Woerle HJ. Efficacy and safety of BI10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60( suppl 1):A271
   Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA briefing document. NDA 204042. Invokana (canagliflozin) Tablets, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf. January 10, 2013. Accessed April 2, 2013
   Google Scholar
• . Hach T, Lambers Heerspink HJ, Pfarr E, . The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes. Paper presented at: 48th Annual Meeting of the European Association for the Study of Diabetes; October 1–5, 2012; Berlin, Germany
   Google Scholar
• . Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP 1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219–1227
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA Briefing Document. NDA 202293. Dapagliflozin tablets, 5 and 10 mg. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf. July 19, 2011. Accessed April 4, 2013
   Google Scholar
• . Folsom AR, Eckfeldt JH, Weitzman S, ; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25(1):66–73
   PubMed Web of Science ®Google Scholar
• . Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78
   PubMed Web of Science ®Google Scholar
• . Goraya TY, Leibson CL, Palumbo PJ, . Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002;40(5):946–953
   PubMed Web of Science ®Google Scholar
• . Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614–1619
   PubMed Web of Science ®Google Scholar
• . Folsom AR, Rasmussen ML, Chambless LE, ; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care. 1999;22(7):1077–1083
   PubMed Web of Science ®Google Scholar
• . Kaarisalo MM, Raiha I, Sivenius J, . Diabetes worsens the outcome of acute ischemic stroke. Diabetes Res Clin Pract. 2005;69(3):293–298
   PubMed Web of Science ®Google Scholar
• . Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–444
   PubMed Web of Science ®Google Scholar
• . Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Teo KK, Pogue J, ; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Adler AI, Stratton IM, Neil HA, . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–419
   PubMed Web of Science ®Google Scholar
• . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . Novi RF, Porta M, Lamberto M, Molinatti GM. Reductions of body weight and blood pressure in obese hypertensive patients treated by diet. A retrospective study. Panminerva Med. 1989;31(1):13–15
   PubMed Web of Science ®Google Scholar
• . Schotte DE, Stunkard AJ. The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med. 1990;150(8):1701–1704
   PubMedGoogle Scholar
• . Staessen J, Fagard R, Amery A. The relationship between body weight and blood pressure. J Hum Hypertens. 1988;2(4):207–217
   PubMed Web of Science ®Google Scholar
• . Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41(2):319–327
   PubMed Web of Science ®Google Scholar
• . Wing RR, Lang W, Wadden TA, ; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486
   PubMed Web of Science ®Google Scholar
• . Han TS, Richmond P, Avenell A, Lean ME. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int J Obes Relat Metab Disord. 1997;21(2):127–134
   PubMed Web of Science ®Google Scholar
• . Stevens VJ, Corrigan SA, Obarzanek E, ; The TOHP Collaborative Research Group. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. Arch Intern Med. 1993;153(7):849–858
   PubMedGoogle Scholar
• . Stevens VJ, Obarzanek E, Cook NR, ; Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1–11
   PubMed Web of Science ®Google Scholar
• . Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl. 2005;7( suppl L):L21–L26
   Web of Science ®Google Scholar
• . Poobalan A, Aucott L, Smith WC, . Effects of weight loss in overweight/obese individuals and long-term lipid outcomes—a systematic review. Obes Rev. 2004;5(1):43–50
   PubMedGoogle Scholar
• . Doehner W, Erdmann E, Cairns R, . Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012;162(1):20–26
   PubMed Web of Science ®Google Scholar
• . Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224–235
   PubMed Web of Science ®Google Scholar
• . Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362–372
   PubMed Web of Science ®Google Scholar
• . Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6
   PubMed Web of Science ®Google Scholar
• . Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3
   PubMed Web of Science ®Google Scholar
• . Patil HR, Al Badarin FJ, Shami HA, . Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–833
   PubMed Web of Science ®Google Scholar
• . Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909–917
   PubMed Web of Science ®Google Scholar
• . Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22
   PubMed Web of Science ®Google Scholar
• . Monami M, Cremasco F, Lamanna C, . Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011;215764
   PubMedGoogle Scholar
• . Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188
   PubMed Web of Science ®Google Scholar
• . Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10(12):1221–1238
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Benjamin IJ, Burke GL, . Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–1146
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34(4):1348–1359
   PubMed Web of Science ®Google Scholar
• . Forst T, Guthrie R, Goldenberg R, . Efficacy and safety of canagliflozin in subjects with type 2 diabetes on metformin and pioglitazone. Paper presented at: World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy); November 8–11, 2012; Barcelona, Spain
   Google Scholar
• . Matthews DR, Fulcher G, Perkovic V, . Efficacy and safety of canagliflozin (CAN A), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-onto insulin therapy +/– oral agents in type 2 diabetes. Paper presented at: 48th Annual Meeting of the European Association for the Study of Diabetes; 1–5 October, 2012; Berlin, Germany
   Google Scholar
• . Stenlof K, Cefalu WT, Kim KA, . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382
   PubMed Web of Science ®Google Scholar
• . Wilding J, Mathieu C, Deng L, . Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea. Paper presented at: 48th Annual Meeting of the European Association for the Study of Diabetes; October 1–5 2012; Berlin, Germany
   Google Scholar
• . Bailey CJ, Iqbal N, T'Joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–959
   PubMed Web of Science ®Google Scholar
• . Bolinder J, Ljunggren O, Kullberg J, . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031
   PubMed Web of Science ®Google Scholar
• . Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–456
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, ; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Heise T, Seewaldt-Becker E, Macha S, . Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes [published online ahead of print January 28, 2013]. Diabetes Obes Metab
   Google Scholar
• . Fonseca VA, Ferrannini E, Wilding JP, . Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus [published online ahead of print December 28, 2012]. J Diabetes Complications
   Google Scholar
• . Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403–409
   PubMed Web of Science ®Google Scholar
• . Zambrowicz B, Freiman J, Brown PM, . LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158–169
   PubMed Web of Science ®Google Scholar